therapeutics

Osiris posted net income of $4.4 million, or 13 cents per share, from a year ago profit of $15.7 million, or 48 cents per share. Analysts expected a profit of 9 cents per share.

Osiris is currently developing a product called Prochymal, which is composed of stem cells taken from adult bone marrow, and is seeking regulatory approval for the product.

Osiris Therapeutics (OSIR) is down 2.33% to $6.70 on a 72% drop in Q4 net income compared with last year, but earnings still topped the mean analyst estimate.

Officials from Nektar Therapeutics (NASDAQ:NKTR) announced that the company's chief operating officer, Bharatt Chowrira, is leaving his post at the firm effective January 3rd, Bloomberg reports Friday. Chowrira will reportedly rec

Repros Therapeutics (RPRX) is up after it says it submitted to the FDA a reanalysis of the previously completed 200 subject trial ZA-003 of Androxal in the treatment of secondary hypogonadism.
An outside statistician who did

Repros Therapeutics (RPRX) has seen its market value soar by more than half to a new 52-week high of $4.16, after it says it completed two animal model studies of the use of Proellex in a vaginally administered formulation that de

ARYx earlier acted to reduce operating expenses ahead of the FDA deciding whether to approve naronapride for U.S. sales, although several former fulltime employees continue to work with the company as consultants, specifically ass

Aryx Therapeutics Inc. (ARYX) is up 19% this morning after the company late last week tried to calm investor concerns by saying it is continuing work on naronapride, ARYx's lead drug candidate, and that the four top executives at

Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) announced that it completed a pre-NDA assessment with the FDA and intends to accelerate its new drug application for NORTHERA, which treats symptomatic, neurogenic orthostatic

Good Morning. It's Friday, December 17, 2010. At this hour, U.S. equity futures are pointing to a lower open. Overseas, the Asian markets were mixed, while the European markets are mostly to the downside. In the headlines.. Moody'